Type 2 diabetes is an impairment in the way the body controls and utilizes sugar (glucose). This chronic (long-term) illness causes an excess of sugar to circulate in the blood. Over time, issues with the cardiovascular, neurological, and immune systems may result from high blood sugar levels. The purpose of this research was to determine how diabetes mellitus (DM) affected a few biochemical variables as well as how those variables affected one another. This study included 50 patients suffering from diabetic mellitus and another 50 healthy subjects. Insulin, preptin, and myostatin levels were evaluated using the commercial ELISA kit. Glycated hemoglobin, fasting blood sugar (FBS), cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very-low-density lipoprotein (VLDL) were estimated using biochemical tests. Patients suffering from DM showed higher levels of FBS, glycated hemoglobin (HbA1c), insulin, insulin resistance, preptin, cholesterol, triglyceride, HDL, LDL, VLDL, and myostatin than in controls, 156.9880 vs 91.1440, 7.5660 vs 5.1560, 13.9190 vs 6.3408, 8.5928 vs 4.3254, 77.0955 vs 35.8797, 211.5625 vs 120.4149, 215.0857 vs 80.8269, 66.003 vs 26.539, 102.5416 vs 77.7102, 43.0171 vs 16.1654, and 6.303 vs 0.313, respectively. The levels of the studied parameters also showed a significant positive correlation between each other, except the correlations between HOMO-IR and each of preptin, insulin, triglycerides, LDL, and VLDL.
Key words: correlation, Homo-IR, LDL, triglycerides, VLDL
*Corresponding author: Noora Wael Rasheed, Department of Medical Laboratory Techniques, Al Rafidain University College, Baghdad, Iraq. Email: [email protected]
Submitted: 24 October 2022. Accepted: 10 November 2022. Published: 25 January 2023.
©2023 Rasheed NW
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (http://creativecommons.org/licenses/by-nc/4.0/)
It is reasonable to think that one of the most ancient human diseases is diabetes mellitus (DM). The metabolic syndrome originally included type 2 diabetes as one of its symptoms in 1988.1 The characteristics of type 2 diabetes include hyperglycemia, insulin resistance, and a relative insulin deficit, the most common form of DM.2 Before, type 2 diabetes was thought to be an insulin-independent condition. This condition is caused by the interaction of environmental, genetic, and behavioral risk factors.3 The primary contributing factors to type 2 diabetes are genetics and lifestyle decisions.4 The formation of type 2 diabetes is widely acknowledged to be influenced by a number of lifestyle factors, which include binge drinking, smoking, physical inactivity, and sedentary lifestyle.5 According to reports, obesity is the root cause of around 55% of type 2 DM (T2DM) cases.6 It is believed that the growth in juvenile obesity between the 1960s and 2000s contributed to the rise in T2DM in children and adolescents.7 Environmental toxins might be a contributing factor to the recent rise in type 2 diabetes incidence. Bisphenol A, a component of several plastics, has been shown to have a marginally positive correlation with the frequency of type 2 diabetes.8
Furthermore, despite the fact that studies have shown a high association between childhood obesity and type 2 diabetes, there is still much to learn about this connection. Although experts are currently looking into the connection between type 2 diabetes and environmental contaminants, it is still evident that there is a significant connection between the growing incidence of juvenile obesity and type 2 diabetes in children and adolescents. Preptin was discovered in rat experiments for the first time in 2001. Along with insulin, the pancreatic beta cells produce this peptide hormone, which has 34 amino acids.9 Preptin, an endocrine peptide, is thought to activate the insulin-like growth factor receptor 2 (IGF2R), which, together with protein C and phospholipase C, results in calcium-dependent insulin secretion when the level of glucose is high.10 Similar to insulin, preptin also influences bone metabolism by increasing cellular differentiation and changing the function of osteoblasts and osteoclasts.11 Preptin is involved in metabolic functions. In T2DM patients, preptin has been the focus of only a very limited number of studies.
This study included 50 patients suffering from diabetic mellitus, who attended the Baghdad Teaching Hospital, for therapy or for checking their status. All subjects who were included in this study were notified of the research purpose, and another 50 healthy subjects were involved in the research for comparison of results, as controls.
Blood samples were taken from both controls and patients. The sample collection was done during the fasting status of the subjects using disposable syringes. The drawn blood was divided into two parts, the first part (2 ml) was kept in the EDTA tube (to perform glycated hemoglobin [HBA1c] analysis), while the second part was kept in the gel tube (3 ml) for about 15 min, centrifuged at 1500– 2000 ×g for 5 min, and was then transferred into a new plane tube and stored at (−20°C).
Calculation of body mass index (BMI) was done by dividing the square of the height: BMI = weight (kg)/height (m2).
The fasting blood glucose levels of all patients and controls were checked in accordance with the Braham and Tindoer (1972) theory. According to this theory, glucose oxidase converts glucose to gluconate, which releases hydrogen peroxide. Following this reaction, quinonimine is produced, which is detected spectrophotometrically at 505 nm by reacting hydrogen peroxide with phenol and 4-aminoantipyrine in the presence of peroxidase.
Using the NycoCard Reader II, the amount of HbA1c was measured in all patients and controls.
The total blood cholesterol was measured using the Biolabo laboratory kit; the method of measurement was based on enzymatic hydrolysis. The amount of the produced red dye quinonimide is related to the level of cholesterol; quinonimine absorbance was measured using a spectrophotometer at 500 nm.
Glycerol and fatty acids were digested by enzymes to identify the triglycerides. The amount of red dye quinonimide produced was inversely related to the level of cholesterol. Using a spectrophotometer, the quinonimine absorbance was measured at 500 nm.
Using Friedwald’s method, LDL cholesterol may be quantitatively determined from total cholesterol, triglycerides, and the concentration of HDL cholesterol. The formula for calculating LDL is as follows:
LDL = Total Cholesterol − HDL Cholesterol − Triglyceride/5.
VLDL concentration was equal to one-fifth of serum TG.
Insulin levels were estimated by following the instructions provided by the ELISA commercial kit (E0010Hu), the preptin levels were estimated using the kit, E1448Hu, and levels of myostatin in serum were estimated using the commercial kit E0403Hu.
The distribution of the studied samples according to demographic parameters is shown in Table 1. According to age group, the distribution showed nonsignificant difference between the control and patients (chi-square = 1.661, P = 0.894). The results of sample distribution according to the blood groups and gender also showed nonsignificant difference (chi-square = 4.262, P = 0.748 and chi-square = 1.46, P = 0.157, respectively) between studied groups. The patients’ samples recorded a significant (P = 0.001) higher BMI (33.3 ± 0.86) compared to that of the control (28.4 ± 0.89).
TABLE 1. Distribution of samples according to age, blood group, gender, and BMI difference between patient and control samples.
| Parameter | Group | Chi-square | P | ||
|---|---|---|---|---|---|
| Patients | Control | ||||
| Age | <20 | 2 | 3 | 1.661 | 0.894 |
| 21–30 | 11 | 13 | |||
| 31–40 | 6 | 8 | |||
| 41–50 | 8 | 9 | |||
| 51–60 | 10 | 8 | |||
| >61 | 13 | 9 | |||
| Blood | A+ | 7 | 6 | 4.262 | 0.748 |
| A− | 2 | 5 | |||
| B+ | 4 | 1 | |||
| B− | 8 | 7 | |||
| AB+ | 12 | 13 | |||
| AB− | 2 | 2 | |||
| O+ | 15 | 15 | |||
| O− | 0 | 1 | |||
| Gender | Male | 25 | 31 | 1.46 | 0.157 |
| Female | 25 | 19 | |||
| BMI | 33.3 ±0.86 | 28.4 ± 0.89 | - | 0.001 | |
BMI, body mass index.
The results of studied parameters are shown in the table 2. Fasting blood sugar amounts in the patients were considerably (0.001) higher than that of the controls (156.9880 vs 91.1440). Additionally, HbA1c levels in patients were substantially (0.001) higher than in controls (7.5660 vs 5.1560). Insulin levels were somewhat greater in patients compared to healthy subjects (13.9190 vs 6.3408). Insulin resistance levels in patients were much greater than that of controls (8.5928 vs 4.3254). Preptin levels were significantly greater in patients than that of controls (77.0955 vs 35.8797). Patients’ cholesterol and triglyceride levels were substantially greater than those of the control group (211.5625 vs 120.4149 and 215.0857 vs 80.8269, respectively). The patients’ HDL, LDL, and VLDL values were much greater than those of the control group (66.003 vs 26.539, 102.5416 vs 77.7102, 43.0171 vs 16.1654, respectively). The patients’ myostatin levels were also greater than those of controls (6.303 vs 0.313).
TABLE 2. Comparison of serum levels of the studied parameter in patients and control.
| Group | Mean | SE | P | |
|---|---|---|---|---|
| BS | Patients | 156.9880 | 9.60498 | 0.001 |
| Control | 91.1440 | 1.37674 | ||
| HbA1c | Patients | 7.5660 | 0.21271 | 0.001 |
| Control | 5.1560 | 0.11422 | ||
| Insulin | Patients | 13.9190 | 0.61094 | 0.918 |
| Control | 6.3408 | 0.50367 | ||
| HOMA-IR | Patients | 8.5928 | 1.28206 | 0.002 |
| Control | 4.3254 | 0.95238 | ||
| Preptin | Patients | 77.0955 | 4.39009 | 0.001 |
| Control | 35.8797 | 1.23347 | ||
| Cholesterol | Patients | 211.5625 | 3.05717 | 0.164 |
| Control | 120.4149 | 4.08512 | ||
| Triglyceride | Patients | 215.0857 | 3.55867 | 0.001 |
| Control | 80.8269 | 5.77451 | ||
| HDL | Patients | 66.0038 | 0.42192 | 0.001 |
| Control | 26.5392 | 2.06743 | ||
| LDL | Patients | 102.5416 | 3.32350 | 0.05 |
| Control | 77.7102 | 4.52219 | ||
| VLDL | Patients | 43.0171 | 0.71173 | 0.001 |
| Control | 16.1654 | 1.15490 | ||
| Myostatin | Patients | 6.3033 | 0.46801 | 0.001 |
| Control | 0.3130 | 0.01592 | ||
BS, blood sugar; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein.
Pearson correlation among the studied biochemical parameters was done and the results are summarized in Table 3. The results showed a significant positive correlation among all the lipid profile levels and with insulin level, myostatin, preptin, HbA1c, and FBS, and among each of them. Only the level of insulin resistance failed to show a significant correlation with the other parameters.
TABLE 3. Correlation of the serum levels among the studied parameters.
| Parameter | BS | HBa | Insulin | HOMA-IR | Preptin | Cholesterol | Triglyceride | HDL | LDL | VLDL | Myostatin | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BS | R | 1 | 0.783** | 0.410** | 0.573** | 0.318** | 0.520** | 0.465** | 0.494** | 0.300** | 0.465** | 0.558** |
| Sig. | 0.000 | 0.000 | 0.000 | 0.001 | 0.000 | 0.000 | 0.000 | 0.002 | 0.000 | 0.000 | ||
| HBa | R | 1 | 0.506** | 0.367** | 0.396** | 0.693** | 0.616** | 0.609** | 0.436** | 0.616** | 0.645** | |
| Sig. | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||
| Insulin | R | 1 | 0.122 | 0.419** | 0.625** | 0.570** | 0.629** | 0.328** | 0.570** | 0.542** | ||
| Sig. | 0.228 | 0.000 | 0.000 | 0.000 | 0.000 | 0.001 | 0.000 | 0.000 | ||||
| HOMA-IR | R | 1 | 0.051 | 0.199* | 0.182 | 0.199* | 0.105 | 0.182 | 0.294** | |||
| Sig. | 0.616 | 0.047 | 0.070 | 0.047 | 0.297 | 0.070 | 0.003 | |||||
| Preptin | R | 1 | 0.591** | 0.652** | 0.584** | 0.262** | 0.652** | 0.444** | ||||
| Sig. | 0.000 | 0.000 | 0.000 | 0.008 | 0.000 | 0.000 | ||||||
| Cholesterol | R | 1 | 0.777** | 0.782** | 0.755** | 0.777** | 0.693** | |||||
| Sig. | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||||
| Triglyceride | R | 1 | 0.779** | 0.265** | 1.000** | 0.682** | ||||||
| Sig. | 0.000 | 0.008 | 0.000 | 0.000 | ||||||||
| HDL | R | 1 | 0.221* | 0.779** | 0.701** | |||||||
| Sig. | 0.027 | 0.000 | 0.000 | |||||||||
| LDL | R | 1 | 0.265** | 0.335** | ||||||||
| Sig. | 0.008 | 0.001 | ||||||||||
| VLDL | R | 1 | 0.682** | |||||||||
| Sig. | 0.000 | |||||||||||
| Myostatin | R | 1 | ||||||||||
| Sig. | ||||||||||||
BS, blood sugar; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein. * significant difference, ** highly significant
Diabetes mellitus is a metabolic illness with many different etiologies, characterized by the presence of persistent hyperglycemia as well as disruptions in the metabolism of proteins, lipids, and carbohydrates, which is brought on by a problem with insulin production, activity, or both.12
Protein, lipid, and carbohydrate metabolism are all affected differently by insulin. It promotes the absorption and metabolism of glucose by adipocytes in adipose tissue, while activating glucose uptake by cells and glycogen synthesis in muscles.13 It also accelerates the utilization of glucose by the liver and its storage as glycogen.14 This mechanism of action by insulin was supported by the current study which revealed higher insulin levels in the patients. Additionally, the insulin levels were significantly correlated with the elevation of lipid profile tests, preptin levels, and myostatin.
The function of lipoprotein lipase, which needs insulin for tissue production, is to purify plasma lipids. In adipose tissues and the liver, the latter promotes lipogenesis while preventing lipolysis. Additionally, insulin reduces the rate of circulating amino acids by increasing the cellular absorption of amino acids. This is done by stimulating the activation of amino acids and mRNA ribosomal reading, as well as by boosting protein synthesis, which is accomplished by lowering proteolysis.15 As seen by the findings, this means that insulin deficiency (T1DM) or insulin resistance (T2DM) causes elevated lipoprotein levels.
Myostatin levels in diabetic patients have been studied previously, which showed a significant difference in levels between patients and control and also a significant correlation between insulin levels and lipid profile. A previous study showed that compared to normal children, those with T1DM had considerably increased levels of myostatin in blood. The increase in myostatin levels may be attributed to homeostatic mechanism, reduced muscle function, or problems with glucose metabolism.16 The above results disagreed with the findings of a previous study17 which revealed a significantly lower myostatin levels (P = 0.001) in DM2 patients compared to healthy controls. Additionally, the levels of myostatin, fasting plasma glucose (P = 0.005), and lipids (P = 0.028) were shown to be negatively correlated, which contradicted with the results of our study. The results of the current study agreed with a previous study that showed these patients had elevated levels of myostatin compared to the controls (2710.60 ± 559.09 vs 2246.37 ± 416.40, P < 0.001).18
The results also showed a significant elevation of preptin which agreed with a previous study that proved high concentrations of preptin in obese–overweight adults compared with healthy controls. The samples of patients involved in this study revealed them to be overweight (BMI = 33.3 ± 0.86), and the results also correlated with fasting insulin and HOMA-IR.19 Additionally, our results were consistent with those of Aslan et al. (2011),17 who discovered a strong positive correlation between preptin concentration and fasting insulin in individuals with gestational diabetes. Additionally, Yang et al.20 showed that preptin and insulin resistance may be related in individuals who have just been diagnosed with T2DM. Preptin and HOMA-IR were found to be positively correlated in the study findings by Bu et al.,21 while preptin and insulin were not correlated, indicating that preptin may contribute to the etiology of insulin resistance without influencing insulin production.
From the results of this study, we can conclude that patients with DM2 have higher levels of FBS, HbA1c, lipid profile, insulin, preptin, Homo-IR, and myostatin. This increment was also accompanied with a positive correlation among the biochemical parameters as a cascade of biochemical events.
1. Patlak M. New weapons to combat an ancient disease: Treating diabetes. FASEB J. 2002;16:1853. 10.1096/FJ.02-0974BKT
2. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: A review of current trends. Oman Med J. 2012;27(4):269–73. 10.5001/omj.2012.68
3. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus–Present and future perspectives. Nat Rev Endocrinol. 2011;8(4):228–36. 10.1038/NRENDO.2011.183
4. Choy M, Lam S. Sitagliptin: A novel drug for the treatment of type 2 diabetes. Cardiol Rev. 2007;15:264–71. 10.1097/CRD.0b013e318123f771
5. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl Med. 2001;345(11):790–97. 10.1056/NEJMOA010492
6. Gregg EW, Cheng YJ, Narayan KMV, Thompson TJ, Williamson DF. The relative contributions of different levels of overweight and obesity to the increased prevalence of diabetes in the United States: 1976–2004. Prev Med (Baltim). 2007;45:348–52. 10.1016/j.ypmed.2007.07.020
7. Barlow SE; Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: Summary report. Pediatrics. 2007;120 Suppl 4:S164–92. 10.1542/PEDS.2007-2329C
8. Lang IA, Galloway TS, Scarlett A, Henley WE, Depledge M, Wallace RB, et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA. 2008;300(11):1303–10. 10.1001/JAMA.300.11.1303
9. Aydin S. Three new players in energy regulation: Preptin, adropin and irisin. Peptides. 2014;56: 94–110. 10.1016/J.PEPTIDES.2014.03.021
10. Cheng KC, Li YX, Asakawa A, Ushikai M, Kato I, Sato Y, et al. Characterization of preptin-induced insulin secretion in pancreatic beta-cells. J Endocrinol. 2012;215:43–9. 10.1530/JOE-12-0176
11. Chen G, Shi L, Cai L, Lin W, Huang H, Liang J, et al. Comparison of insulin resistance and β-cell dysfunction between the young and the elderly in normal glucose tolerance and prediabetes population: A prospective study. Horm Metab Res. 2017;49(2):135–41. 10.1055/s-0042-111325
12. Ferdi NEH, Abla K, Chenchouni H. Biochemical profile of an adult diabetic population from Algeria in relation with anthropometric parameters, age and gender. Iran J Public Health. 2018;47(8): 1119–27.
13. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133–223. 10.1152/PHYSREV.00063.2017
14. Chadt A, Al-Hasani H. Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease. Pflugers Arch. 2020; 472(9):1273–98. 10.1007/S00424-020-02417-X
15. Grabner GF, Xie H, Schweiger M, Zechner R. Lipolysis: Cellular mechanisms for lipid mobilization from fat stores. Nat Metab. 2021;3:1445–65. 10.1038/s42255-021-00493-6
16. Efthymiadou A, Vasilakis IA, Giannakopoulos A, Chrysis D. Myostatin serum levels in children with type 1 diabetes mellitus. Hormones (Athens). 2021;20:777–82. 10.1007/S42000-021-00317-Y
17. García-Fontana B, Reyes-García R, Morales-Santana S, Ávila-Rubio V, Muñoz-Garach A, Rozas-Moreno P, et al. Relationship between myostatin and irisin in type 2 diabetes mellitus: A compensatory mechanism to an unfavourable metabolic state? Endocrine. 2015;52(1):54–62. 10.1007/S12020-015-0758-8
18. Ahmad SNS, Nourollahi S, Nakhjavani M, Khojastehfard M, Mostafazadeh M, Hajipour H, et al. Preptin and myostatin independently increase in pre-diabetics and patients of type 2 diabetes mellitus. Acta Med Iran. 2019;57(3):160–6. 10.18502/ACTA.V57I3.1818
19. El-Eshmawy M, Abdel Aal I. Relationships between preptin and osteocalcin in obese, overweight, and normal weight adults. Appl Physiol Nutr Metab. 2015; 40:218–22. 10.1139/APNM-2014-0338
20. Yang G, Li L, Chen W, Liu H, Boden G, Li K. Circulating preptin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Ann Med. 2009;41(1):52–6. 10.1080/07853890802244142
21. Bu Z, Kuok K, Meng J, Wang R, Xu B, Zhang H. The relationship between polycystic ovary syndrome, glucose tolerance status and serum preptin level. Reprod Biol Endocrinol. 2012;10:10. 10.1186/1477-7827-10-10